Last Published:  11/23/20 11:55:12 AM (Central)
Short Title: Biological Countermeasure Mitigator
Responsible HRP Element: Space Radiation
Collaborating Org(s):
Funding Status: Completed - Task completed and produced a deliverable
Procurement Mechanism(s):
Solicited
Aims:
  1. To use a lung cancer susceptible mouse model that develops significantly more invasive lung tumors when high LET is provided in fractionated/protracted doses over 5 to 10 days (e.g 0.2 Gy x 5 days or 0.1 Gy x 10 days 56Fe 1GeV, compared to single acute 1 Gy 56Fe). Our objective is to determine if pretreatment with BARD prior to acute or fractionated IR reduces the number of invasive (e.g. more lethal) cancers. We will examine at least 3 different ions.
  2. To test Bardoxylone methyl (BARD) as a Biological Countermeasures (BCM) in mouse models exposed to SPE simulations. As part of the UT Southwestern Lung NSCOR and the Georgetown GI NSCOR, we have lung cancer and colon cancer susceptible mice that have been treated with solar particle simulations. We propose to test if providing BARD to these animals before irradiation reduces the incidence or progression of cancer.
  3. To test BARD as a radiation mitigator by providing it to mice within 60 minutes after irradiation. We will compare SPE simulations (total body exposure 2 Gy Protons) and at least two other ions (56Fe at 600 meV, LET 175 and 28Si at 300 MeV LET 70).
Resources (None Listed)
Mappings
RiskRisk of Acute (In-flight) and Late Central Nervous System Effects from Radiation Exposure
You are here!TaskA Novel Biological Countermeasure and Mitigator of High LET-Induced Cancer Progression

RiskRisk of Cardiovascular Disease and Other Degenerative Tissue Effects From Radiation Exposure and Secondary Spaceflight Stressors
You are here!TaskA Novel Biological Countermeasure and Mitigator of High LET-Induced Cancer Progression

RiskRisk of Radiation Carcinogenesis
You are here!TaskA Novel Biological Countermeasure and Mitigator of High LET-Induced Cancer Progression